

# John A Ormiston Mbchb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6180229/publications.pdf>

Version: 2024-02-01

38  
papers

1,717  
citations

331670

21  
h-index

315739

38  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1640  
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-eluting stents for coronary bifurcations: Bench testing of provisional side-branch strategies. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 49-55.	1.7	162
2	A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 766-776.	2.8	145
3	Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 515-523.	1.7	137
4	Drug-eluting stents for coronary bifurcations: Insights into the crush technique. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 63, 332-336.	1.7	135
5	Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 3-12.	1.7	134
6	First-in-human implantation of a fully bioabsorbable drug-eluting stent: The BVS poly-L-lactic acid everolimus-eluting coronary stent. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 128-131.	1.7	118
7	Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. <i>EuroIntervention</i> , 2010, 6, 447-453.	3.2	116
8	The FRONTIER Stent Registry. <i>Journal of the American College of Cardiology</i> , 2005, 46, 592-598.	2.8	71
9	Hemodynamics in Idealized Stented Coronary Arteries: Important Stent Design Considerations. <i>Annals of Biomedical Engineering</i> , 2016, 44, 315-329.	2.5	59
10	Vascular Compliance Changes of the Coronary Vessel Wall After Bioresorbable Vascular Scaffold Implantation in the Treated and Adjacent Segments. <i>Circulation Journal</i> , 2012, 76, 1616-1623.	1.6	57
11	Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. <i>Journal of the American College of Cardiology</i> , 2017, 70, 60-74.	2.8	51
12	Revascularization for Unprotected Left Main Disease. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1576-1588.	2.8	49
13	Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: Insights from the ABSORB and SPIRIT trials. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 219-228.	1.7	46
14	Impact of bifurcation angle and other anatomical characteristics on blood flow – A computational study of non-stented and stented coronary arteries. <i>Journal of Biomechanics</i> , 2016, 49, 1570-1582.	2.1	44
15	A computational atlas of normal coronary artery anatomy. <i>EuroIntervention</i> , 2016, 12, 845-854.	3.2	43
16	The AST petal dedicated bifurcation stent: First-in-human experience. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 335-340.	1.7	40
17	First-in-Human Evaluation of a Bioabsorbable Polymer-Coated Sirolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1026-1034.	2.9	32
18	Coronary bifurcation stenting: insights from in vitro and virtual bench testing. <i>EuroIntervention</i> , 2010, 6, J53-J60.	3.2	30

#	ARTICLE	IF	CITATIONS
19	First human use of the TAXUs Petal paclitaxel-eluting bifurcation stent. <i>EuroIntervention</i> , 2010, 6, 46-53.	3.2	29
20	Bench testing and coronary artery bifurcations: a consensus document from the European Bifurcation Club. <i>EuroIntervention</i> , 2018, 13, e1794-e1803.	3.2	28
21	A Study of Coronary Bifurcation Shape in a Normal Population. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 82-90.	2.4	22
22	Absorbable coronary stents. <i>Lancet, The</i> , 2007, 369, 1839-1840.	13.7	21
23	IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 914-918.	1.7	18
24	Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E674-E682.	1.7	18
25	Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). <i>American Journal of Cardiology</i> , 2016, 117, 532-538.	1.6	17
26	Serial Assessment by Optical Coherence Tomography of Early and Late Vascular Responses After Implantation of an Absorbable-Coating Sirolimus-Eluting Stent (from the First-in-Human DESSOLVE I) <i>Tj ETQq0 0 0 rgt /Overl</i>	1.6	10
27	Transcatheter Aortic Valve Implantation In Patients With a Large Aortic Annulus. <i>Heart Lung and Circulation</i> , 2018, 27, e11-e14.	0.4	15
28	Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold: the ABSORB cohort B MSCT substudy. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 870-879.	1.2	13
29	Construction of a Coronary Artery Atlas from CT Angiography. <i>Lecture Notes in Computer Science</i> , 2014, 17, 513-520.	1.3	11
30	A novel paclitaxel-eluting dedicated bifurcation stent: A case report from the first human use Taxus Petal trial. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 637-640.	1.7	8
31	Lessons from the real bench: non-BRS. <i>EuroIntervention</i> , 2015, 11, V27-V30.	3.2	8
32	Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 1141-1150.	1.7	5
33	Transcatheter aortic valve implantation in end-stage renal disease. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 247-249.	2.9	4
34	The Petal dedicated bifurcation stent. <i>EuroIntervention</i> , 2010, 6, J139-J142.	3.2	4
35	The value of CT cardiac angiography and CT calcium score testing in a modern cardiology service in New Zealand: a report of a single centre eight-year experience from 5,237 outpatient procedures. <i>New Zealand Medical Journal</i> , 2016, 129, 22-32.	0.5	4
36	Bifurcation Coronary Lesions and the "Crush" Technique. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2566-2567.	2.8	3

#	ARTICLE	IF	CITATIONS
37	Coronary balloon catheter tip damage. A bench study of a clinical problem. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 883-889.	1.7	3
38	A Review of a Regional Primary Percutaneous Coronary Intervention Service, with a Focus on Door to Reperfusion Times: The 2012 Auckland/Northland Experience. <i>Heart Lung and Circulation</i> , 2015, 24, 11-20.	0.4	2